U.S. Physical Therapy, Inc. USPH
84.84
1.08
1.29%
as of 25 Sep
- Market cap
- $1.3B
- P/E
- 499×
Follow USPH
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
35.69 | 54.99 | 149.92 | 404.00 |
P/S ratio |
1.70 | 1.52 | 1.43 | 1.27 | |
P/FCF ratio |
22.70 | 19.43 | 17.05 | 16.15 | |
P/Operating CF |
64.77 | 47.53 | 298.56 | 30.11 | |
P/B ratio |
2.56 | 2.48 | 2.42 | 2.30 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.86 | 1.67 | 1.64 | 1.51 | |
EV/EBITDA |
12.45 | 11.89 | 12.71 | 12.34 | |
EV/Operating CF |
20.31 | 17.35 | 15.59 | 14.76 | |
EV/FCF |
24.81 | 21.35 | 19.54 | 19.13 | |
Quick Ratio |
1.06 | 0.89 | 1.07 | 1.12 | |
Current Ratio |
1.20 | 1.01 | 1.19 | 1.27 | |
Net Debt/EBITDA |
3.85 | 5.44 | 8.91 | 6.81 | |
Debt/Assets |
12.66% | 12.67% | 15.62% | 17.25% | |
Debt/Equity |
0.30 | 0.32 | 0.41 | 0.48 | |
Asset Turnover |
0.68 | 0.66 | 0.66 | 0.67 | |
Operating CF/Net income |
1.52 | 4.48 | (2.07) | 9.03 | |
Capex/Depreciation |
(0.73) | (0.83) | (0.88) | (0.89) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
8.83% | 8.94% | 9.22% | 8.88% | |
Intangible Assets out of Total Assets |
0.72 | 0.72 | 0.72 | 0.72 | |
Share Based Compensation of Revenue |
1.15% | 1.05% | 1.16% | 1.48% | |
Graham Net Nets |
(0.43) | (0.50) | (0.56) | (0.64) | |
Graham Number |
42.17 | 31.69 | 18.66 | 10.68 | |
Earnings Yield |
2.80% | 1.82% | 0.67% | 0.25% | |
Free Cash Flow Yield |
4.41% | 5.15% | 5.86% | 6.19% | |
Revenue per Share |
12.97 | 13.36 | 13.07 | 14.20 | |
Operating CF per Share |
1.31 | 1.64 | 0.25 | 2.28 | |
Capex per Share |
(0.28) | (0.26) | (0.35) | (0.36) | |
Free Cash Flow per Share |
1.03 | 1.38 | (0.10) | 1.92 | |
Cash per Share |
2.05 | 2.34 | 1.88 | 1.65 | |
Shareholders Equity per Share |
33.20 | 31.43 | 30.95 | 29.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
33.20 | 31.43 | 30.95 | 29.81 | |
Free Cash Flow |
15.63 | 21.01 | (1.56) | 29.01 | |
Working Capital |
23.36 | 0.95 | 21.81 | 29.77 | |
Capital Expenditures |
(4.31) | (3.93) | (5.37) | (5.36) | |
Net Current Asset Value |
(553.05) | (587.13) | (633.51) | (660.03) | |
EV/EBIT |
15.76 | 15.02 | 16.38 | 16.02 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.03 | |
Net Profit Margin |
6.66% | 2.75% | (0.93%) | 1.78% | |
Price to Operating Income |
14.42 | 13.67 | 14.30 | 13.53 | |
| Other line items | |||||
Average Receivables |
84.19 | 87.00 | 93.81 | 95.77 | |
Average Payables |
6.89 | 6.00 | 6.42 | 5.56 | |
Average Assets |
1,112.73 | 1,185.74 | 1,210.87 | 1,214.24 | |
Average Common Equity |
494.45 | 483.45 | 484.20 | 475.73 |
Columns are period end dates